Summary
Global Markets Direct’s, ‘Kidney Fibrosis - Pipeline Review, H1 2016’, provides an overview of the Kidney Fibrosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Kidney Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Kidney Fibrosis
- The report reviews pipeline therapeutics for Kidney Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Kidney Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Kidney Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Kidney Fibrosis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc.
Angion Biomedica Corp.
Bio-inRen
BiOrion Technologies B.V.
Epigen Biosciences, Inc.
Evotec AG
Galectin Therapeutics, Inc.
GenKyoTex S.A.
GNI Group Ltd.
Intercept Pharmaceuticals, Inc.
Isarna Therapeutics GmbH
Lpath, Inc.
MorphoSys AG
Pharmaxis Limited
ProMetic Life Sciences Inc.
Raptor Pharmaceutical Corp.
Regulus Therapeutics Inc.
SciFluor Life Sciences, LLC
Symic Biomedical, Inc.
Tobira Therapeutics, Inc.
Vascular Biogenics Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Kidney Fibrosis Overview 10
Therapeutics Development 11
Pipeline Products for Kidney Fibrosis – Overview 11
Pipeline Products for Kidney Fibrosis – Comparative Analysis 12
Kidney Fibrosis – Therapeutics under Development by Companies 13
Kidney Fibrosis – Therapeutics under Investigation by Universities/Institutes 15
Kidney Fibrosis – Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Kidney Fibrosis – Products under Development by Companies 18
Kidney Fibrosis – Products under Investigation by Universities/Institutes 20
Kidney Fibrosis – Companies Involved in Therapeutics Development 21
AbbVie Inc. 21
Angion Biomedica Corp. 22
Bio-inRen 23
BiOrion Technologies B.V. 24
Epigen Biosciences, Inc. 25
Evotec AG 26
Galectin Therapeutics, Inc. 27
GenKyoTex S.A. 28
GNI Group Ltd. 29
Intercept Pharmaceuticals, Inc. 30
Isarna Therapeutics GmbH 31
Lpath, Inc. 32
MorphoSys AG 33
Pharmaxis Limited 34
ProMetic Life Sciences Inc. 35
Raptor Pharmaceutical Corp. 36
Regulus Therapeutics Inc. 37
SciFluor Life Sciences, LLC 38
Symic Biomedical, Inc. 39
Tobira Therapeutics, Inc. 40
Vascular Biogenics Ltd. 41
Kidney Fibrosis – Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
ANG-3070 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ANG-3586 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ANG-4011 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ANG-4021 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Antisense RNAi Oligonucleotide to Inhibit MicroRNA-21 for Hepatocellular Carcinoma, Kidney Fibrosis and Myocardial Fibrosis - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
BOT-191 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BRN-1889 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
cenicriviroc mesylate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
CT-140 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
cysteamine DR - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Drug to Inhibit Galectin-3 for Fibrosis - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Drugs for Tissue Fibrosis - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
F-351 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
GKT-136901 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
GRMD-02 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
ICG-001 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
INT-767 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
ISTH-0047 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
LJ-1888 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Lpathomab - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
MOR-107 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
P-007 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
PBI-4050 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
PBI-4419 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Protein to Activate BMP-7 for Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
PXS-4820 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
PXS-5033A - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
RG-012 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
SB-300 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Small Molecules for Fibrosis - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Small Molecules to Inhibit SphK2 for Oncology, Kideny Disease, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
SOL-1 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
VB-703 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Kidney Fibrosis – Recent Pipeline Updates 106
Kidney Fibrosis - Dormant Projects 134
Kidney Fibrosis – Product Development Milestones 135
Featured News & Press Releases 135
Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics 135
Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting 135
Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe 136
Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015 137
Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases 138
Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting 138
Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 139
Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 140
Nov 01, 2012: Prometic Life Sciences Presents Positive Data On New Anti-fibrotic Drug PBI-4419 At American Society Of Nephrology Annual Meeting 140
Oct 20, 2010: GNI Receives F351 Patent Allowance in Japan 140
Appendix 141
Methodology 141
Coverage 141
Secondary Research 141
Primary Research 141
Expert Panel Validation 141
Contact Us 141
Disclaimer 142
List of Tables
Number of Products under Development for Kidney Fibrosis, H1 2016 11
Number of Products under Development for Kidney Fibrosis – Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Development by Companies, H1 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2016 20
Kidney Fibrosis – Pipeline by AbbVie Inc., H1 2016 21
Kidney Fibrosis – Pipeline by Angion Biomedica Corp., H1 2016 22
Kidney Fibrosis – Pipeline by Bio-inRen, H1 2016 23
Kidney Fibrosis – Pipeline by BiOrion Technologies B.V., H1 2016 24
Kidney Fibrosis – Pipeline by Epigen Biosciences, Inc., H1 2016 25
Kidney Fibrosis – Pipeline by Evotec AG, H1 2016 26
Kidney Fibrosis – Pipeline by Galectin Therapeutics, Inc., H1 2016 27
Kidney Fibrosis – Pipeline by GenKyoTex S.A., H1 2016 28
Kidney Fibrosis – Pipeline by GNI Group Ltd., H1 2016 29
Kidney Fibrosis – Pipeline by Intercept Pharmaceuticals, Inc., H1 2016 30
Kidney Fibrosis – Pipeline by Isarna Therapeutics GmbH, H1 2016 31
Kidney Fibrosis – Pipeline by Lpath, Inc., H1 2016 32
Kidney Fibrosis – Pipeline by MorphoSys AG, H1 2016 33
Kidney Fibrosis – Pipeline by Pharmaxis Limited, H1 2016 34
Kidney Fibrosis – Pipeline by ProMetic Life Sciences Inc., H1 2016 35
Kidney Fibrosis – Pipeline by Raptor Pharmaceutical Corp., H1 2016 36
Kidney Fibrosis – Pipeline by Regulus Therapeutics Inc., H1 2016 37
Kidney Fibrosis – Pipeline by SciFluor Life Sciences, LLC, H1 2016 38
Kidney Fibrosis – Pipeline by Symic Biomedical, Inc., H1 2016 39
Kidney Fibrosis – Pipeline by Tobira Therapeutics, Inc., H1 2016 40
Kidney Fibrosis – Pipeline by Vascular Biogenics Ltd., H1 2016 41
Assessment by Monotherapy Products, H1 2016 42
Number of Products by Stage and Target, H1 2016 44
Number of Products by Stage and Mechanism of Action, H1 2016 46
Number of Products by Stage and Route of Administration, H1 2016 48
Number of Products by Stage and Molecule Type, H1 2016 50
Kidney Fibrosis Therapeutics – Recent Pipeline Updates, H1 2016 106
Kidney Fibrosis – Dormant Projects, H1 2016 134
List of Figures
Number of Products under Development for Kidney Fibrosis, H1 2016 11
Number of Products under Development for Kidney Fibrosis – Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 17
Assessment by Monotherapy Products, H1 2016 42
Number of Products by Top 10 Targets, H1 2016 43
Number of Products by Stage and Top 10 Targets, H1 2016 43
Number of Products by Top 10 Mechanism of Actions, H1 2016 45
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 45
Number of Products by Routes of Administration, H1 2016 47
Number of Products by Stage and Routes of Administration, H1 2016 47
Number of Products by Top 10 Molecule Types, H1 2016 49
Number of Products by Stage and Top 10 Molecule Types, H1 2016 49
